

# Immunodominance

The Choice of the Immune System

*Edited by Jeffrey A. Frelinger*



WILEY-VCH Verlag GmbH & Co. KGaA



**Immunodominance**

*Edited by*  
*Jeffrey A. Frelinger*

## ***Related Titles***

Frosch, M., Maiden, M. C. J. (Eds.)

### **Handbook of Meningococcal Disease**

**Infection Biology, Vaccination, Clinical Management**

2006

ISBN 3-527-31260-9

Hamann, A., Engelhardt, B. (Eds.)

### **Leukocyte Trafficking**

**Molecular Mechanisms, Therapeutic Targets, and Methods**

2005

ISBN 3-527-31228-5

Lutz, M., Romani, N., Steinkasserer, A. (Eds.)

### **Handbook of Dendritic Cells**

**Biology, Diseases and Therapies**

2006

ISBN 3-527-31109-2

Kaufmann, S. H. E. (Ed.)

### **Novel Vaccination Strategies**

2004

ISBN 3-527-30523-8

Meager, A. (Ed.)

### **The Interferons**

**Characterization and Application**

2006

ISBN 3-527-31180-7

Kalden, J. R., Herrmann, M. (Eds.)

### **Apoptosis and Autoimmunity**

**From Mechanisms to Treatments**

2003

ISBN 3-527-30442-8

Pollard, K. M. (Ed.)

### **Autoantibodies and Autoimmunity**

**Molecular Mechanisms in Health and Disease**

2005

ISBN 3-527-31141-6

Kropshofer, H., Vogt, A.B. (Eds.)

### **Antigen Presenting Cells**

**From Mechanisms to Drug Development**

2005

ISBN 3-527-31108-4

# Immunodominance

The Choice of the Immune System

*Edited by Jeffrey A. Frelinger*



WILEY-VCH Verlag GmbH & Co. KGaA

#### The Editor

**Prof. Dr. Jeffrey A. Frelinger**

Department of Microbiology and Immunology  
University of North Carolina  
CB# 7290 Jones  
Chapel Hill, NC 27599-7290  
USA

#### Cover

Shifts in repertoire and immunodominance following primary and secondary exposures to antigen. For further details see Figure 6.6 on page XXII.

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for  
**British Library Cataloguing-in-Publication Data**  
A catalogue record for this book is available from the British Library.

#### **Bibliographic information published by Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>.

© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages).  
No part of this book may be reproduced in any form – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Typesetting** Kühn & Weyh, Satz und Medien, Freiburg

**Printing** betz-druck GmbH, Darmstadt

**Binding** Litges und Dopf Buchbinderei GmbH, Heppenheim

Printed in the Federal Republic of Germany.  
Printed on acid-free paper.

**ISBN-13:** 978-3-527-31274-0

**ISBN-10:** 3-527-31274-9

## Contents

Preface XIII

List of Contributors XV

Color Plates XIX

I	<b>Mechanics of Antigen Processing</b>	1
1	<b>Class I MHC Antigen Processing</b>	3
	<i>Peter J. Miller and Edward J. Collins</i>	
1.1	Introduction	3
1.2	Properties of MHC	3
1.2.1	Structure of MHC	3
1.2.2	Polymorphic Residues Generate Specificity Pockets	5
1.3	Properties of Peptides	6
1.3.1	Peptides That Bind Are Not Random Sequences	6
1.3.2	Peptide-binding Motifs	6
1.3.3	Peptide Length Is Limited in Class I MHC Peptides	7
1.3.4	Binding Affinity	7
1.3.5	Molecular Recognition	9
1.3.6	Epitope Prediction	9
1.4	Cytosolic Processing	10
1.4.1	The Proteasome	10
1.4.2	The Immunoproteasome	12
1.4.3	Opening the Immunoproteasome	13
1.4.4	Peptide Trimming	14
1.4.5	Association of the Proteasome with the Endoplasmic Reticulum	15
1.5	Peptide Transport	15
1.5.1	Transport via TAP	16
1.5.2	TAP Selectivity	16
1.5.3	TAP-independent Peptide Transport	17

- 1.5.3.1 Endogenous Peptides 17
- 1.5.3.2 Exogenous Peptides 18
- 1.6 Class I MHC Maturation and Peptide Loading 19
  - 1.6.1 ER Chaperones: Calnexin, Calreticulin, ERp57, and Tapasin 19
    - 1.6.1.1 Calnexin 19
    - 1.6.1.2 Tapasin 19
    - 1.6.1.3 ERp57 21
    - 1.6.1.4 Calreticulin 21
  - 1.6.2 Peptide Loading 21
- 1.7 Immunodominance and Class I MHC Peptide Processing 22

**2 The Mechanics of Class II Processing: Establishment of a Peptide Class II Hierarchy 31**

*James R. Drake and Andrea J. Sant*

- 2.1 General Overview 31
  - 2.1.1 Immunodominance and Crypticity 31
  - 2.1.2 The Impact of T-Cell Repertoire in the Experimental Analysis of Immunodominance 33
  - 2.1.3 Different Antigen-presenting Cells Have Different Functions 34
  - 2.1.4 The Phases of Antigen Processing 35
- 2.2 Phase I: MHC Class II Biosynthesis and Delivery to Peptide-loading Compartments 36
  - 2.2.1 Invariant Chain Isoforms 36
  - 2.2.2 Effects of Cell Signaling on MHC Class II Transport 37
- 2.3 Phase II: Antigen Internalization and Processing 38
  - 2.3.1 BCR-mediated Antigen Internalization 39
  - 2.3.2 Dendritic Cells and Macrophages 40
- 2.4 Phase III: Formation and Expression of Antigenic Peptide by MHC Class II Molecules 41
  - 2.4.1 Proteolytic Antigen Processing 41
  - 2.4.2 Class II Peptide Loading 43
    - 2.4.2.1 DM 44
    - 2.4.2.2 DO 45
    - 2.4.2.3 DO-, DM-, and BCR-Mediated Antigen Processing 46
    - 2.4.2.4 The Distribution of MHC Class II and Other Proteins Within MIIC 46
  - 2.4.3 Cell-surface Delivery of Peptide–Class II Complexes 47
    - 2.4.3.1 Exosomes 48
    - 2.4.3.2 Signaling Properties of Peptide–Class II Complexes 49
- 2.5 Conclusions 50
- Acknowledgments 50



<b>3</b>	<b>The Phenomenon of Immunodomination: Speculations on the Nature of Immunodominance</b>	<b>57</b>
	<i>Alessandro Sette and Roshni Sundaram</i>	
3.1	Introduction	57
3.2	MHC Binding, Cellular Processing, and T-Cell Repertoire are Major Determinants of Immunodominance	58
3.3	Previous Systematic Analysis of Immunodominance by Our Group	59
3.4	Cellular and Molecular Events in Immunodomination	62
3.5	Speculations on the Mechanism of Immunodomination	63
3.5.1	Involvement of APCs	63
3.5.2	Possible Involvement of the Immune Synapse in Immunodomination	65
3.5.3	The Potential Role of MTOC in Immunodomination	67
3.6	Significance of Studying Immunodominance for Vaccine Development	67
3.7	Conclusions	68
<b>II</b>	<b>Proteasome Specificity and Immuno-Proteasomes</b>	<b>73</b>
<b>4</b>	<b>Endogenous Antigen Processing</b>	<b>75</b>
	<i>Jonathan W. Yewdell</i>	
4.1	Unbottling the Genie	75
4.2	DRiPs to the Rescue	76
4.3	The Ubiquitin–Proteasome Pathway	77
4.4	Pressing TDH Questions	80
4.4.1	Answer to Question 1	80
4.4.2	The Real World	81
4.4.3	Answer to Question 2	82
4.5	What Does This Have to Do With Immunodominance?	84
<b>III</b>	<b>Effect of the T Cell Repertoire on Dominance</b>	<b>89</b>
<b>5</b>	<b>Regulation of Early T-Cell Development in the Thymus</b>	<b>91</b>
	<i>Thomas M. Schmitt and Juan Carlos Zúñiga-Pflücker</i>	
5.1	Introduction	91
5.2	<i>T-Cell Development in the Thymus</i>	92
5.2.1	Early T-Cell Progenitors	95
5.2.2	Thymocyte Migration	96
5.2.3	Factors Regulating T-cell Development	97
5.2.4	Notch and T-cell Development	98

- 5.3 In Vitro *T*-cell Development 100
- 5.4 Concluding Remarks 101
  
- 6 CD8 T-cell Immunodominance, Repertoire, and Memory 109**  
*Dalia E. Gaddis, Michael J. Fuller, and Allan J. Zajac*

  - 6.1 Introduction 109
  - 6.2 CD8 T-Cell Responses and Memory 111
  - 6.3 Analyzing the Memory Repertoire 114
  - 6.4 Immunodominance 116
    - 6.4.1 Antigen-related Factors 117
    - 6.4.2 T Cell-related Factors 119
  - 6.5 Epitope-dependent Skewing of the Repertoire During Primary, Memory, and Recall Responses 120
  - 6.6 Heterologous Infections and Immunodominance 125
  - 6.7 Chronic Infections and T-cell Heterogeneity 127
  - 6.8 Repertoire Limitation and Immunodominance 131
  - 6.9 Impact of Epitope Variation 133
  - 6.10 Concluding Remarks 135

  
- IV Effects of Pathogens on the Immune Response 147**
  
- 7 *Listeria monocytogenes* Infection and the CD8<sup>+</sup> T-Cell Hierarchy 149**  
*Brandon B. Porter and John T. Harty*

  - 7.1 Introduction 149
  - 7.2 Innate Immune Response to LM 150
  - 7.3 Adaptive Immune Response to LM and Ag Presentation 151
  - 7.4 Secreted Versus Non-secreted Ag 152
  - 7.5 The Hierarchy of the CD8<sup>+</sup> T-cell Responses to LM Epitopes 153
  - 7.6 IFN- $\gamma$  and the CD8<sup>+</sup> T-cell Hierarchy 156
  - 7.7 Timing of Ag Presentation and the CD8<sup>+</sup> T-cell response 158
  - 7.8 Conclusions 160
  - Acknowledgments 161

  
- 8 Immunodominance in Tuberculosis 163**  
*David M. Lewinsohn and JoAnne L. Flynn*

  - 8.1 Immune Responses to *Mycobacterium tuberculosis* 163
  - 8.2 B Cells 164
  - 8.3 CD4 T Cells 164
  - 8.4 CD8 T Cells 165
  - 8.5 Antigen Processing and Presentation of Mtb Antigens 166
  - 8.6 How Does Infection with Mtb Differ from Other Acute or Chronic Infections? 168

8.7	Immunodominance in the CD4 T-cell Response	169
8.7.1	Human	169
8.7.2	Mouse	170
8.8	Immunodominance in the CD8 T-cell Response	171
8.8.1	Human	171
8.8.2	Mouse	174
8.9	Non-classically Restricted T Cells in TB	176
8.10	Conclusions and Implications for Future Research	177
	Acknowledgments	178
<b>9</b>	<b>T-Cell Specificity and Respiratory Virus Infections</b>	<b>189</b>
	<i>Sherry R. Crowe and David L. Woodland</i>	
9.1	Introduction	189
9.2	Primary Immune Responses to Respiratory Virus Infections	190
9.3	Specificity of the Primary Immune Response	191
9.4	T-Cell Memory to Respiratory Virus Infections	195
9.5	The Specificity of Memory T Cells	197
9.6	Recall Responses to Secondary Infections	198
9.7	Immunodominance Patterns in Recall Responses	199
9.8	Modification of Immunodominance Hierarchies by Vaccination	201
9.9	Conclusions	202
	Acknowledgments	203
<b>10</b>	<b>Effects of Pathogens on the Immune Response: HIV</b>	<b>209</b>
	<i>Masafumi Takiguchi</i>	
10.1	Introduction	209
10.2	Identification of HIV-1 CTL Epitopes	211
10.2.1	Identification of HIV-1 CTL Epitopes by a Strategy Using Overlapping Peptides	212
10.2.2	Identification of HIV-1 CTL Epitopes by the Strategy of Reverse Immunogenetics	215
10.3	Immunodominant HIV-1 Epitopes Presented by HLA Alleles Associated With Slow Progression to AIDS and Their Escape Mutants	216
10.3.1	HLA-B*57-restricted Immunodominant Epitopes and Their Escape Mutants	216
10.3.2	HLA-B*27-restricted Immunodominant Epitopes	218
10.3.3	HLA-B*51-restricted Immunodominant Epitopes	218
10.4	Immunodominant HIV-1 Epitopes Presented by HLA Alleles Associated With Rapid Progression to AIDS	219
10.5	Immunodominant HIV-1 Epitopes Presented by Other HLA Alleles	219
10.5.1	HLA-A*02-restricted Immunodominant Epitopes	219
10.5.2	HLA-B*08-restricted Immunodominant Epitopes	220

- 10.6 Escape Mutations and Viral Fitness 220
- 10.7 Effect of Nef-mediated HLA Class I Downregulation on Recognition of HIV-1-infected CD4<sup>+</sup> T Cells by HIV-1-specific CD8<sup>+</sup> T Cells 222
- 10.8 Skewed Maturation of HIV-1-specific CD8<sup>+</sup> T Cells 224

## **11 The Effects of Pathogens on the Immune System:**

### **Viral Hepatitis 233**

*Mala Maini and Antonio Bertoletti*

- 11.1 Introduction 233
- 11.2 The Viruses and the Disease 233
  - 11.2.1 Genomic Organization 233
  - 11.2.2 Prevalence 233
  - 11.2.3 Hepatic Disease and Chronicity After Infection 235
- 11.3 Importance of CD4 and CD8 T Cells in HBV and HCV Control 235
- 11.4 Limitations of Existing Data 236
  - 11.4.1 Low Frequency of HBV- and HCV-specific T Cells 237
  - 11.4.2 Pre-selection of Epitopes 237
  - 11.4.3 Stage of Infection 238
  - 11.4.4 Variations in Viral Inoculum 238
- 11.5 Hierarchy of T-cell Responses During HBV Infection: Helper CD4 T-cell Response 238
- 11.6 Hierarchy of T-cell Responses During HBV Infection: Cytotoxic T-cell Response 240
- 11.7 Hierarchy of HCV Proteins 243
- 11.8 Hierarchy of HCV Epitopes 244
- 11.9 Immunodominance and Liver Pathology 248
- 11.10 Concluding Remarks 249

## **12 Immunodominance in the T-Cell Response to Herpesviruses 255**

*Michael W. Munks and Ann B. Hill*

- 12.1 Introduction 255
- 12.2 General Considerations 256
  - 12.2.1 Herpesviruses: A Brief Virological Primer 256
  - 12.2.2 A General Framework for Thinking About Immunodominance in the T-Cell Response to Herpesvirus Infections 258
- 12.3 Immunodominance in the CD8 T-Cell Response to the Three Classes of Herpesvirus 260
  - 12.3.1 Alphaherpesviruses 260
    - 12.3.1.1 Human Studies: Immunodominance of Structural Virion Proteins that can be Presented in the Face of Immune Evasion 260
    - 12.3.1.2 Mouse Studies of HSV 261
    - 12.3.1.3 The Remarkable Immunodominance of gB-SSIEFARL in B6 Mice 262

12.3.2	Betaherpesviruses	263
12.3.2.1	The Acute CD8 T-Cell Response to MCMV	263
12.3.2.2	The Memory CD8 T-Cell Response to MCMV Becomes More Focused Over Time	264
12.3.2.3	The Impact of Interference With Antigen Presentation by MCMV's Vp1s on the CD8 T-Cell Response	265
12.3.2.4	The Memory T-Cell Response to HCMV	267
12.3.2.5	Increasing Size and Oligoclonality of the CD8 T-cell Response to HCMV With Age	268
12.3.2.6	What Accounts for Memory “Inflation” and TCR V $\beta$ Focusing?	268
12.3.3	HCMV and Immunosenescence	271
12.3.4	T-Cell Cross-reactivity Between Betaherpesviruses	272
12.3.5	Gammaherpesviruses	272
12.3.6	Epstein-Barr Virus	273
12.3.6.1	Interference with the MHC Class I Pathway by EBV	273
12.3.6.2	Overview of the Response to Lytic and Latent Proteins	274
12.3.6.3	Immunodominance Hierarchy for the Acute Response to Lytic Cycle Proteins	274
12.3.6.4	Kinetics of the Response to Lytic Proteins	276
12.3.6.5	Immunodominance Hierarchy of the Response to Latent Proteins	276
12.3.6.6	Kinetics of the Response to Latent Proteins	277
12.3.6.7	Immunodominance of the LC13 TCR in Responding to HLA-B8/FLRGRAYGL: An Extreme Example of TCR Immunodominance	278
12.4	Concluding Remarks	279
	<b>Index</b>	<b>285</b>



## Preface

The normal, intact immune system does not have equal probability of responding to every potential part of a protein. It has been known for more than 50 years that only parts of the protein that are “outside” are available for antibody binding. Yet, with the advent of Western blotting techniques, antibodies that react with the interior of the protein have been routinely produced. Although not all epitopes are equally easy to produce, or are equally protective in infection, nearly any structure can be an antibody epitope.

In contrast to antibodies, T cells must recognize fragments of proteins bound to MHC molecules. In T-cell responses against viruses, very few epitopes are easily identified. In the case of LCMV, the immune response in BALB/c mice uses only a single MHC class I protein: L. K and D are not used at all. This is not because there are no suitable peptides that can bind K and D proteins, as BALB/c mice that lack L make an excellent response to LCMV. Furthermore, only a single peptide from the LCMV genome accounts for more than 90% of the CD8 T cells responding to infection. Because LCMV has a coding size of approximately 3500 amino acids, the immune system fixates 9 of 3500 amino acids, or about 0.2% of the coding capacity.

This fixation on a small part of the potential antigenic space is not unique to LCMV in BALB/c mice. Most pathogens in inbred mice show similar immunodominance. Even in response to bacteria, where the pathogen genome size is much larger, dominance is observed. The CD8 T-cell response to *Listeria monocytogenes* infection is dominated by very few epitopes in both C57Bl/6 and BALB/c mice. With a genome size of almost three million base pairs, the majority of the response is restricted to two or three epitopes. The immune system is choosing only about 0.002% of the coding sequence to recognize.

Why is this so? Clearly, there are many mechanisms at work. In this volume we cover topics including (1) the mechanisms of antigen processing, i.e., how pathogen molecules are converted to molecules that are targets for cell-mediated immunity; (2) binding of processed peptides to MHC molecules, a critical step in their expression on the cell surface; and (3) the role of the pathogen itself in modifying the immune response by interfering with antigen processing and the downstream immune responses.

We have not yet completed the puzzle of immunodominance, but the chapters here represent our current understanding of its pieces.

I thank Andreas Sendtko for encouragement and enthusiasm for this book.

Jeffrey A. Frelinger

Chapel Hill, October 2005



## List of Contributors

**Antonio Bertolletti**

Institute of Hepatology  
University College London  
69-75 Cheries Mews  
London WC1E 6HX  
United Kingdom

**Edward J. Collins**

Department of Biochemistry and  
Biophysics and Department of Micro-  
biology and Immunology  
University of North Carolina at  
Chapel Hill  
CB#7290  
804 M.E. Jones Building  
Chapel Hill  
North Carolina 27599  
USA

**Sherry R. Crowe**

Trudeau Institute  
154 Algonquin Avenue  
Saranac Lake  
New York 12983  
USA

**James R. Drake**

University of Rochester  
School of Medicine and Dentistry  
601 Elmwood Avenue  
Box 609  
Rochester  
New York 14642  
USA

**JoAnne L. Flynn**

Department of Molecular Genetics and  
Biochemistry  
University of Pittsburgh School of  
Medicine  
Pittsburgh  
Pennsylvania 15261  
USA

**Michael J. Fuller**

Center for Vaccines and Immunity  
Columbus Children's Research  
Institute  
700 Children's Drive  
Columbus, OH 43205  
USA

**Dalia E. Gaddis**

Department of Microbiology  
University of Alabama at Birmingham  
845 Nineteenth Street South  
446 BBRB  
Birmingham  
Alabama 35294  
USA

**John T. Harty**

Interdisciplinary Program in  
Immunology and  
Department of Microbiology  
University of Iowa  
Iowa City  
Iowa 52242  
USA

**Ann B. Hill**

Oregon Health Sciences University  
Department of Molecular Microbiology  
and Immunology  
3181 SW Sam Jackson Park Rd  
L 220  
Portland OR 97281  
USA

**David M. Lewinsohn**

Pulmonary and Critical Care Medicine  
Oregon Health & Science University  
Portland VA Medical Center  
Portland  
Oregon 97239  
USA

**Mala Maini**

Infection and Immunity  
Windeyer Institute of Medical Science  
University College of London  
London WC1T 4JF  
United Kingdom

**Peter J. Miller**

Department of Biochemistry and  
Biophysics  
University of North Carolina at Chapel  
Hill  
CB#7260  
405 M.E. Jones Building  
Chapel Hill  
North Carolina 27599  
USA

**Michael W. Munks**

Integrated Department of Immunology  
National Jewish Medical and Research  
Center  
1400 Jackson Street  
Denver CO 80206  
USA

**Brandon B. Porter**

Interdisciplinary Program in  
Immunology  
University of Iowa  
Iowa City  
Iowa 52242  
USA

**Andrea J. Sant**

University of Rochester  
School of Medicine and Dentistry  
601 Elmwood Avenue  
Box 609  
Rochester  
New York 14642  
USA

**Thomas M. Schmitt**

University of Washington  
Howard Hughes Medical Institute  
Box 357370  
Seattle, Washington 98795  
USA

**Alessandro Sette**

La Jolla Institute for Allergy and  
Immunology  
3030 Bunker Hill Street  
Suite 326  
San Diego  
California 92109  
USA

**Roshni Sundaram**

Immunosol, Inc.  
10790 Roselle Street  
San Diego  
California 92121  
USA

**Masafumi Takiguchi**

Division of Viral Immunology  
Center for AIDS Research  
Kumamoto University  
2-2-1 Honjo  
Kumamoto 860-0811  
Japan

**David L. Woodland**

Trudeau Institute  
154 Algonquin Avenue  
Saranac Lake  
New York 12983  
USA

**Jonathan W. Yewdell**

Laboratory of Viral Diseases  
National Institute of Allergy and  
Infectious Diseases  
Building 4, Room 211  
Center Drive  
Bethesda  
Maryland 20892  
USA

**Allan J. Zajac**


Department of Microbiology  
University of Alabama at Birmingham  
845 Nineteenth Street South  
446 BBRB  
Birmingham  
Alabama 35294  
USA

**Juan Carlos Zúñiga-Pflücker**

University of Toronto  
Sunnybrook and Women's Research  
Institute  
2075 Bayview Avenue  
Toronto  
Ontario M4N 3M5  
Canada



Color Plates



**Figure 1.3** Production of peptide-loaded class I MHC. Class I MHC heavy chain and  $\beta_2m$  are translocated separately into the ER. Immediately when accessible, Asn86 of the heavy chain is glycosylated, allowing for recognition by the chaperone calnexin. (1) Calnexin also recruits Erp57, which mediates disulfide bond formation in  $\alpha 3$  and  $\alpha 2$  of class I heavy chain. (2) Once the heavy chain is folded and the disulfide bond in  $\alpha 3$  is formed, soluble  $\beta_2m$  binds to class I heavy chain. While the MHC class I molecule is being formed (cycling on and off calnexin), newly translated tapasin associates with


calnexin and ERp57, both of which facilitate its folding and disulfide bond formation. Tapasin with calnexin-ERp57 then binds and stabilizes the TAP1/2 dimer. (3) Upon binding of  $\beta_2m$ , calnexin dissociates and is replaced by calreticulin. The class I heavy chain- $\beta_2m$ -calreticulin-ERp57 heterocomplex then associates with the tapasin-TAP-calnexin-ERp57 heterocomplex. ERp57 remains part of the peptide-loading complex (PLC) until peptide has been loaded, but it is not known whether ERp57 comes with tapasin or the class I molecule. (4) The PLC now consists of TAP, tapasin, heavy chain,  $\beta_2m$ ,

Figure 1.3 (continued)

calreticulin, and Erp57. (5) Proteasomes in the cytosol degrade substrates, generating peptides of varying length. (6) Large proteasomal products can be further cleaved in the cytosol by aminopeptidases such as TPPII. (7) Peptides with affinity for TAP will bind, and ATP-induced conformational changes in TAP will transport it through the ER membrane. (8) ERAP1 performs amino-terminal trimming in the ER. (9) These peptides may go directly into the PLC, or they may be retrotranslocated back into the cytosol through SEC61 and have to enter the ER again via


TAP. (10) If the amino acid motif of the peptide matches the class I MHC molecule, it will then bind in the peptide groove, inducing a conformational change that stabilizes peptide binding. ERp57 will mediate the disulfide formation in  $\alpha 2$ , "locking" the peptide in. (11) If the correct conformational change is induced, all chaperone molecules will dissociate. (12) The trimer of class I heavy chain- $\beta_2m$ -peptide is shuttled from the ER to the Golgi apparatus and subsequently to the plasma membrane of the cell.

(This figure also appears on page 20.)




**Figure 2.1** General pathway of exogenous antigen processing. Depicted is the general pathway of exogenous antigen processing and presentation. Numbered yellow circles indicate steps of the pathway at which variations can occur that will alter the hierarchy of peptide-class II complexes expressed by the APC (see text for details). (1) Relative levels of li isoforms (i.e., p31li vs. p41li, Section 2.2.1); (2) Effects of cell signaling (Sections 2.2.2 and 2.3); (3) Receptor-mediated antigen internalization and intracellular trafficking

(Section 2.3); (4) Proteolytic processing of internalized antigen (Section 2.4.1); (5) Role of DM and DO in class II peptide loading (Section 2.4.2); (6) Intravesicular distribution of processing proteins (Section 2.4.2.4); (7) Exosomes and the cell-surface delivery of peptide-class II complexes (Section 2.4.3) (8) MHC class II signaling and partitioning of peptide-class II complexes into membrane microdomains (Section 2.4.3.2). PM: plasma membrane; EE: early endosome  
(This figure also appears on page 32.)




**Figure 3.1** Possible mechanisms involved in immunodomination (a) Preemption of critical elements of the synapse by the dominant T cell. (b) Engagement of inhibitory receptors by the submissive T cell. (c) Lack of adequate directed secretion of APC factors. T<sub>D</sub> = domi-

nant T cell; T<sub>S</sub> = submissive T cell TCR/MHC molecules are shown in red, costimulator ligands and receptors in blue, inhibitory receptors in orange, APC factors in white. (This figure also appears on page 20.)



**Figure 6.6** Shifts in repertoire and immunodominance following primary and secondary exposures to antigen. As primary immune responses are initiated, antigen-specific T cells become activated and expand in number. This results in a discernable shift in the T-cell repertoire as antigen-specific cells, indicated here in red, green, and blue, increase in frequency. A contraction phase ensues, following clearance of the inducing antigen; however, this downsizing is typically proportional. Consequently, the skewing of the repertoire and -


the hierarchy of immunodominance that develops during the expansion phase are imprinted on the memory pool. This phenomenon is sometimes referred to as immunological scarring. Although the repertoire and hierarchies of the primary effector and memory pools are usually similar, marked differences can arise following rechallenges. In this illustration, the red responders become most dominant. (This figure also appears on page 120.)



**Figure 6.8** Continuous antigenic stimulation can drive responding CD8 T cells to deletion. Certain foreign antigens are not rapidly removed by the actions of the host's immune response. This is perhaps best exemplified by persistent viral infections. In these instances an initial response becomes detectable, resulting in repertoire shifts and the development of immunodominance. If the infection is not cleared by the overall immune

response, then the responding cells may be subject to repetitive antigenic stimulation. Under these conditions certain clones and specificities of CD8 T cells may succumb to deletion, resulting in further changes in repertoire and epitope hierarchies. Notably, the deletion of CD8 T cells is exacerbated by the absence of CD4 T-cell help. (This figure also appears on page 128.)







**Figure 9.1** Antigen specificity in the lung airways following influenza virus infection. Three dominant epitopes and seven subdominant epitopes account for approximately 78% of the total CD8<sup>+</sup> T-cell response to influenza virus infection in the lung airways. The remaining 22% of the CD8<sup>+</sup> T-cell response is undetermined at this time. Two dominant and at least seven subdominant epitopes

account for approximately 60% of the total CD4<sup>+</sup> T-cell response to influenza virus infection in the lung airways. The remaining 40% of the CD4<sup>+</sup> T-cell response is undetermined at this time. Some of the CD4<sup>+</sup> T-cell epitopes are listed as putative because detailed characterization of the epitopes has not yet been performed. (This figure also appears on page 192.)


1. Identification of motif of HLA-B\*3501-binding peptides




2. Synthesis of HIV-1 8-mer to 10-mer peptides carrying B\*3501 binding peptide motif




3. Identification of B\*3501-binding HIV-1 peptides by a peptide binding assay



4. Induction of HIV-1 peptide-specific CTLs in PBMC from HIV-1-infected, HLA-B\*3501+ Patients



5. Killing of HIV-1-infected cells or HIV-1-recombinant vaccinia-infected cells by peptide-specific CTLs



◀ **Figure 10.4** Identification of HLA-B\*3501-restricted HIV-1 CTL epitopes by a method using reverse immunogenetics. (1) HLA-B\*3501 molecules are isolated from HLA-negative cell lines transfected with the HLA-B\*3501 gene. Peptides are eluted from isolated HLA-B\*3501 molecules, and then the eluted peptides are sequenced to determine immunodominant HIV-1 epitopes. (2) The motif of HLA-B\*3501-binding peptides. HLA-B\*3501-binding peptide possessed Pro at position 2 and hydrophobic residues Tyr, Phe, Met, Leu, and Ile at the C-terminus. (3) 8-mer to 11-mer HIV-1 sequences carrying the HLA-B\*3501 anchor residues at position 2 and the C-terminus are selected and synthesized. (4) Synthesized HIV-1 peptides are tested for binding to HLA-B\*3501 by a peptide-binding assay such as the HLA class I stabilization assay. (5) HLA-B\*3501-binding peptides are further used to induce peptide-specific CTLs from PBMCs of HLA-B\*3501-positive, HIV-1-infected individuals. The PBMCs are stimulated with each

HLA-B\*3501-binding peptide or cocktails of the peptides. Peptide-stimulated PBMCs are cultured for approximately 14 days. Peptide-specific CTLs or CD8<sup>+</sup> T cells are identified by measuring the cytotoxic activity of cultured PBMCs toward peptide-pulsed cells or by measuring the production of IFN- $\gamma$  by CD8<sup>+</sup> T cells in cultured PBMCs stimulated with peptide-pulsed cells. The peptides showing a positive response are considered epitope candidates. (5) To clarify whether the peptides are recognized as naturally occurring peptides by specific CTLs or CD8<sup>+</sup> T cells, cells infected with HIV-1 or HIV-1 recombinant vaccinia virus are used to stimulate IFN- $\gamma$  production or for CTL activity. When peptide-specific T-cell clones or lines kill target cells infected with HIV-1 or HIV-1 recombinant vaccinia virus or produce IFN- $\gamma$  after being stimulated with cells infected with HIV-1 or HIV-1 recombinant vaccinia virus, the peptides that these T cells recognize are concluded to be naturally occurring HIV-1 epitope peptides. (This figure also appears on page 214.)



I  
**Mechanics of Antigen Processing**

